title: Treatment of drug-induced thrombocytopenia.
abstract: Estimates on the incidence of drug-induced thrombocytopenia range 5-40% in patients receiving heparin to < 1% with other causative agents. Systematically assessing drug-induced thrombocytopenia through a series of steps, each step providing additional evidence that the suspected agent is the true cause of thrombocytopenia, is the best way to identify the causative agent. Databases exist to aid in identification of the causative agent. Knowing which medications may be causative agents as well as which are not known to cause drug-induced thrombocytopenia, the aetiologies of drug-induced thrombocytopenia, signs and symptoms of thrombocytopenia and strategies to treat thrombocytopenia associated with specific agents will provide the clinician with the necessary skills to make proper medical decisions.
authors.affiliation: College of Pharmacy, Department of Pharmacy, University of Oklahoma Health Sciences Center, 1110 North Stonewall, Post Office Box 26901, Oklahoma City, OK 73190-5040, USA. patrick-medina@ouhsc.edu
authors.forename: Stacey D
authors.initials: SD
authors.lastname: Zondor
authors.forename: James N
authors.initials: JN
authors.lastname: George
authors.forename: Patrick J
authors.initials: PJ
authors.lastname: Medina
mesh_terms: D000925:Anticoagulants / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006493:Heparin / Q000009:adverse effects*; D006801:Humans; D017370:Interleukin-11 / Q000627:therapeutic use*; D010976:Platelet Count; D017713:Platelet Transfusion; D011994:Recombinant Proteins / Q000627:therapeutic use*; D013921:Thrombocytopenia / Q000139:chemically induced / Q000175:diagnosis / Q000628:therapy
chemical_list: D000925:Anticoagulants; D000970:Antineoplastic Agents; D017370:Interleukin-11; D011994:Recombinant Proteins; D006493:Heparin; C105308:oprelvekin